ReShape Lifesciences, the company behind the stock ticker RSLS, has taken a significant step forward with the receipt of a Notice of Allowance from the U.S. Patent and Trademark Office. This notice pertains to their patent application 18/241,151, which centers on an inventive intragastric balloon system.
The patent, once granted, will encompass innovative claims for a unique intragastric balloon. This device consists of a swallowable capsule that features a self-sealing fill valve and a degradable release valve. Importantly, the release valve is engineered to deflate approximately three months after inflation, facilitating natural excretion. Additional features are included in the patent claims, which collectively contribute to the innovation.
Upon issuance, the patent is expected to extend protection for ReShape Lifesciences into at least January 2031. This duration excludes any potential Patent Term Extension (PTE) that could further lengthen the protection period. The company, trading under the ticker RSLS, stands to benefit from this intellectual property advancement.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Reshape Lifesciences Inc (RSLS, Financial) is $1.00 with a high estimate of $1.00 and a low estimate of $1.00. The average target implies an upside of 173.97% from the current price of $0.37. More detailed estimate data can be found on the Reshape Lifesciences Inc (RSLS) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Reshape Lifesciences Inc's (RSLS, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
